US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Telomir Pharmaceuticals

2.58

+0.04001.57%

Volume:76.06K

Turnover:193.95K

Market Cap:76.79M

PE:-4.61

High:2.70

Open:2.55

Low:2.49

Close:2.54

Loading ...

Overview Company News Filings

BRIEF-Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1

Telomir Pharmaceuticals Inc - Telomir-1 Reverses Copper-Induced Ros Elevation in Human Cell Lines

THOMSON REUTERS

TELO Treatment Amazes in Preclinical Trial

Zacks Small Cap Research

Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) market cap surged US$16m last week, retail investors who have a lot riding on the company were rewarded

Simply Wall St.

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

Zacks Small Cap Research

Renovaro Names Nathen Fuentes as CFO

MT Newswires Live

Telomir announces findings from preclinical progeria lifespan study

BRIEF-Telomir Pharmaceuticals Confirms Lifespan Restoration And Normalization Of Accelerated Aging In Preclinical Model Of Progeria

Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)

Telomir Pharmaceuticals: Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria

THOMSON REUTERS

TELO Continues to Impress

Zacks Small Cap Research

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

Telomir Pharmaceuticals- Confirms Copper-Binding Capabilities of Telomir-1, Expands Pipeline Into Wilson's Disease

THOMSON REUTERS

Telomir Pharmaceuticals Inc - to Submit Ind & Inad Application by Q4 2025, With Clinical Trials Planned for 2026

THOMSON REUTERS

EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease

Telomir Pharmaceuticals Shares Down 12.57% at $4.45 in Premarket Trade; White Diamind Research Says It Has a Strong Sell Rating on the Stock

THOMSON REUTERS

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

Closing Bell Movers: Adobe down over 8% on guidance shortfall

Telomir Pharmaceuticals enters into stock purchase agreement for $1M

Telomir Pharmaceuticals' Shares Rally After Positive Results for Diabetes Treatment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TELO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TELO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TELO\",,,,,undefined,":{"symbol":"TELO","market":"US","secType":"STK","nameCN":"Telomir Pharmaceuticals","latestPrice":2.58,"timestamp":1745523795689,"preClose":2.54,"halted":0,"volume":76055,"delay":0,"floatShares":17618248,"shares":29762671,"eps":-0.559686,"marketStatus":"Trading","change":0.04,"latestTime":"04-24 15:43:21 EDT","open":2.55,"high":2.7,"low":2.485,"amount":193946.06820749998,"amplitude":0.084646,"askPrice":2.58,"askSize":430,"bidPrice":2.55,"bidSize":180,"shortable":3,"etf":0,"ttmEps":-0.559686,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745524800000},"marketStatusCode":2,"adr":0,"listingDate":1707454800000,"exchange":"NASDAQ","adjPreClose":2.54,"postHourTrading":{"tag":"盘后","latestPrice":2.45,"preClose":2.54,"latestTime":"17:25 EDT","volume":1545,"amount":3861.3,"timestamp":1745443515991},"volumeRatio":0.786928},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TELO\",,,,,undefined,":{"symbol":"TELO","floatShares":17618248,"roa":"-250.96%","roe":"-810.18%","lyrEps":-0.559686,"volumeRatio":0.786928,"shares":29762671,"dividePrice":0,"high":2.7,"amplitude":0.084646,"preClose":2.54,"low":2.485,"week52Low":2.38,"pbRate":"119.41","week52High":8.4,"institutionHeld":0,"latestPrice":2.58,"committee":-0.409836,"eps":-0.559686,"divideRate":0,"volume":76055,"delay":0,"ttmEps":-0.559686,"open":2.55,"prevYearClose":4.12,"prevWeekClose":2.48,"prevMonthClose":3.23,"prevQuarterClose":3.23,"fiveDayClose":2.49,"twentyDayClose":4.12,"sixtyDayClose":4.64},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TELO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2506268590","title":"BRIEF-Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2506268590","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506268590?lang=en_us&edition=fundamental","pubTime":"2025-01-28 20:39","pubTimestamp":1738067958,"startTime":"0","endTime":"0","summary":"BRIEF-Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1Jan 28 (Reuters) - Telomir Pharmaceuticals Inc TELO.O:TELOMIR PHARMACEUTICALS INC - ANNOUNCES BREAKTHROUGH RESULTS WITH TELOM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nFWN3OO16I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2506426590","title":"Telomir Pharmaceuticals Inc - Telomir-1 Reverses Copper-Induced Ros Elevation in Human Cell Lines","url":"https://stock-news.laohu8.com/highlight/detail?id=2506426590","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506426590?lang=en_us&edition=fundamental","pubTime":"2025-01-28 20:34","pubTimestamp":1738067678,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nFWN3OO16I:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2507054583","title":"TELO Treatment Amazes in Preclinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2507054583","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507054583?lang=en_us&edition=fundamental","pubTime":"2025-01-28 19:06","pubTimestamp":1738062360,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals  is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, “confirms Telomir-1 can reverse biologic aging, extending life while preserving health.”The company just released potential groundbreaking results from a preclinical study of Telomir-1 on human cell lines. Data from the test showed the ability of Telomir-1 to “fully reverse copper-induced elevation of Reactive Oxygen Species  and provided robust cellular protection against copper toxicity.”This announcement adds to the list of conditions that Telomir-1 has the potential to treat by attacking the underlying causes of the conditions and not just ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telo-treatment-amazes-preclinical-trial-110600677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2503913073","title":"Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) market cap surged US$16m last week, retail investors who have a lot riding on the company were rewarded","url":"https://stock-news.laohu8.com/highlight/detail?id=2503913073","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503913073?lang=en_us&edition=fundamental","pubTime":"2025-01-16 19:25","pubTimestamp":1737026745,"startTime":"0","endTime":"0","summary":"Key Insights Significant control over Telomir Pharmaceuticals by retail investors implies that the general public has...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-telo/telomir-pharmaceuticals/news/telomir-pharmaceuticals-incs-nasdaqtelo-market-cap-surged-us","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PSQ","USAW.SI","IE00BKPKM429.USD","TQQQ","IE00BGHQF748.EUR","QID","LU2210150020.SGD","BK4588","USJW.SI","SQQQ","BK4007","IE00B3QW5Z07.USD","BK4585","NQmain","LU2095319765.USD","NDAQ","NVIW.SI","BK4112","MNQmain","QLD",".IXIC","TELO","LU2210149790.SGD","TSYW.SI","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2503581014","title":"Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503581014","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503581014?lang=en_us&edition=fundamental","pubTime":"2025-01-13 17:00","pubTimestamp":1736758800,"startTime":"0","endTime":"0","summary":"Zacks Small Cap Research was hard at work in 2024 initiating analyst coverage on 40 companies. Each of our initiation reports provides a valuation, investment thesis and financial forecast model that comes from our 11 experienced analysts’ expertise and due diligence. Our work has generated investment ideas in health care, consumer electronics, finance technologies, transportation, AI-based products, and oil and gas production among other industries.The last year has been one fraught with risks, critical elections around the globe and multiple ongoing military conflicts among other material events. Despite this, index performance as measured by the S&P was positive in 2024, with large caps outperforming mid-caps and mid-caps surpassing small caps. Much of the strong performance was driven by tech stocks and the Magnificent Seven while other areas lagged.Ligand Pharmaceuticals  is a royalty aggregator which has a large opportunity set of biopharma names where it can deploy its capital f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-small-cap-research-2024-090000334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","LGND","BK4007","BK4152","BK4166",".IXIC","MNQmain","BK4579","BK4139","USAW.SI","LU0566484027.USD","BK4191","MTVA","QLD","NVIW.SI","TSYW.SI","QID","CPSS","NQmain","TQQQ","LU1559883803.SGD","TWI","USJW.SI","PSQ","TELO","VIOT"],"gpt_icon":1},{"id":"2501783819","title":"Renovaro Names Nathen Fuentes as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2501783819","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501783819?lang=en_us&edition=fundamental","pubTime":"2025-01-07 23:02","pubTimestamp":1736262170,"startTime":"0","endTime":"0","summary":"Renovaro  said Tuesday it has appointed Nathen Fuentes as chief financial officer, replacing interim CFO Simon Tarsh.Fuentes, whose appointment took effect Jan. 2, was previously CFO at Telomir Pharmaceuticals , Renovaro said.Renovaro shares rose 3% in recent Tuesday trading.Price: 1.03, Change: +0.03, Percent Change: +3.30","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RENB","BK4007","BK4139","TELO"],"gpt_icon":0},{"id":"2501204142","title":"Telomir announces findings from preclinical progeria lifespan study","url":"https://stock-news.laohu8.com/highlight/detail?id=2501204142","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501204142?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:52","pubTimestamp":1736257975,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals (TELO) announced findings from a preclinical progeria lifespan study conducted in collaboration with Nagi Bioscience SA. Ut...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/telomir-announces-findings-from-preclinical-progeria-lifespan-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/telomir-announces-findings-from-preclinical-progeria-lifespan-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2501620935","title":"BRIEF-Telomir Pharmaceuticals Confirms Lifespan Restoration And Normalization Of Accelerated Aging In Preclinical Model Of Progeria","url":"https://stock-news.laohu8.com/highlight/detail?id=2501620935","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501620935?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:19","pubTimestamp":1736255983,"startTime":"0","endTime":"0","summary":"Jan 7 (Reuters) - Telomir Pharmaceuticals Inc   :   * TELOMIR PHARMACEUTICALS: CONFIRMS LIFESPAN RESTORATION AND NORMALIZATION OF ACCELERATED AGING IN PRECLINICAL MODEL OF PROGERIASource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2501420615","title":"Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)","url":"https://stock-news.laohu8.com/highlight/detail?id=2501420615","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501420615?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:00","pubTimestamp":1736254800,"startTime":"0","endTime":"0","summary":"MIAMI, FL / ACCESSWIRE / January 7, 2025 / Telomir Pharmaceuticals, Inc.  , an emerging leader in age-reversal science focused on treating the root causes of diseases rather than just their symptoms, announced today potentially groundbreaking findings from a preclinical progeria lifespan study conducted in collaboration with Nagi Bioscience SA. Utilizing C. elegans  models, in which the study demonstrated restoration of shortened lifespan and normalization of accelerated aging with Telomir-1.Laurent Mouchiroud, Ph.D., Co-founder and CSO of Nagi Bioscience SA, commented, \"The analysis confirms that Telomir-1 not only restores lifespan but also effectively counters the decline observed in untreated populations. These findings underscore Telomir-1's potential to transform how we address age-related conditions by targeting their underlying cellular mechanisms.\". Telomir-1: A Novel Therapeutic ApproachTelomir-1 is a groundbreaking small molecule designed to target key causes of cell damage ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telomir-pharmaceuticals-confirms-lifespan-restoration-130000669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","BK4007","GENE","TELO"],"gpt_icon":0},{"id":"2501208041","title":"Telomir Pharmaceuticals: Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria","url":"https://stock-news.laohu8.com/highlight/detail?id=2501208041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501208041?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:33","pubTimestamp":1736253192,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nFWN3O31GV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2501879807","title":"TELO Continues to Impress","url":"https://stock-news.laohu8.com/highlight/detail?id=2501879807","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501879807?lang=en_us&edition=fundamental","pubTime":"2025-01-07 19:35","pubTimestamp":1736249700,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals  is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, “confirms Telomir-1 can reverse biologic aging, extending life while preserving health.”Continuing a string of positive news, the company just released more preclinical results, this time revolving around Progeria research. Progeria, also known as Hutchinson-Gilford Progeria Syndrome, is a rare genetic condition that causes children to experience rapid aging. Fewer than 400 children worldwide are affected by this devastating disease, which leads to growth failure, joint stiffness, cardiovascular complications, and premature death, often in the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telo-continues-impress-113500613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2493842757","title":"Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2493842757","media":"ACCESSWIRE","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493842757?lang=en_us&edition=fundamental","pubTime":"2024-12-23 20:30","pubTimestamp":1734957000,"startTime":"0","endTime":"0","summary":"MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. , or the \"Company\", an emerging leader in age-reversal science, today announced significant findings from its copper binding studies with Telomir-1. This is a promising development as the company explores Telomir-1 for the treatment of Wilson's disease and other copper related disorders. The announcement marks an important step forward in Telomir's mission to address critical unmet medical needs while continuing to explore transformative therapies.The limitations of current therapies underscore the urgent need for new treatment options that address the root cause of Wilson's disease while minimizing side effects. Telomir-1's copper binding properties hold the potential to offer a safer, more effective alternative that directly targets the underlying mechanisms of the disease. The designation of Wilson's disease as a rare and life-threatening condition also positions it as a candidate for orphan drug designation,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telomir-pharmaceuticals-confirms-copper-binding-123000772.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4159","BK4007","TELO","CAGR"],"gpt_icon":0},{"id":"2493756769","title":"Telomir Pharmaceuticals- Confirms Copper-Binding Capabilities of Telomir-1, Expands Pipeline Into Wilson's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2493756769","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493756769?lang=en_us&edition=fundamental","pubTime":"2024-12-23 20:03","pubTimestamp":1734955423,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NO0BP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2493598647","title":"Telomir Pharmaceuticals Inc - to Submit Ind & Inad Application by Q4 2025, With Clinical Trials Planned for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2493598647","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493598647?lang=en_us&edition=fundamental","pubTime":"2024-12-23 20:03","pubTimestamp":1734955423,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NO0BP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2493755072","title":"EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2493755072","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493755072?lang=en_us&edition=fundamental","pubTime":"2024-12-23 19:46","pubTimestamp":1734954389,"startTime":"0","endTime":"0","summary":"On Monday, Telomir Pharmaceuticals, Inc.  announced preclinical findings highlighting the copper-binding potential of its lead compound, Telomir-1, as a promising treatment for Wilson's disease and related disorders. The compound exhibits a binding affinity for copper ions, enabling precise regulation of copper metabolism and interacting with essential ions such as copper, iron, and zinc, the company said.Recent preclinical studies by Recipharm and Smart Assays reveal Telomir-1's strong copper-binding affinity, enabling precise regulation of copper metabolism and interaction with essential ions.According to the company, these findings position Telomir-1 as a potential breakthrough therapy for Wilson's disease, a rare disorder caused by ATP7B mutations leading to toxic copper buildup in vital organs.Offering a safer alternative to current treatments, which have significant side effects and require lifelong adherence, Telomir-1 targets the disease's root cause and may qualify for orphan ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/JfIndsP6dxYW1ows7Z6WoA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/9b4199a6742e42afb264298d24dc0694","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/JfIndsP6dxYW1ows7Z6WoA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/9b4199a6742e42afb264298d24dc0694"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-telomir-pharmaceuticals-reports-potential-114629038.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2491378006","title":"Telomir Pharmaceuticals Shares Down 12.57% at $4.45 in Premarket Trade; White Diamind Research Says It Has a Strong Sell Rating on the Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2491378006","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491378006?lang=en_us&edition=fundamental","pubTime":"2024-12-13 22:07","pubTimestamp":1734098862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nL1N3NE0GU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2490386932","title":"Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2490386932","media":"ACCESSWIRE","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490386932?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:30","pubTimestamp":1734010200,"startTime":"0","endTime":"0","summary":"Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth potential.MIAMI, FL / ACCESSWIRE / December 12, 2024 / Telomir Pharmaceuticals, Inc.  , an emerging leader in age-reversal science, today announced it has raised $1 million in equity funding through The Starwood Trust. The investment, structured as a straightforward common stock transaction, was made at $7 per share representing a 20% premium to the closing price on the date of execution and included no warrants. The restricted shares further emphasize The Starwood Trust's confidence in the company's long-term strategy and potential.This funding builds upon the $5 million non-dilutive line of credit extended by The Starwood Trust earlier this year, which remains undrawn. Together, these financial milestones reflect Telomir's commitment to advancing its innovative pipeline while aiming to maintain a strong financial foundation.Telomir recen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telomir-pharmaceuticals-raises-1-million-133000480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2490781490","title":"Closing Bell Movers: Adobe down over 8% on guidance shortfall","url":"https://stock-news.laohu8.com/highlight/detail?id=2490781490","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490781490?lang=en_us&edition=fundamental","pubTime":"2024-12-12 07:00","pubTimestamp":1733958018,"startTime":"0","endTime":"0","summary":"Check out this evening’s top movers from around Wall Street, compiled by The Fly.  HIGHER – Telomir Pharmaceuticals (TELO) up 7.8% after annou...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/closing-bell-movers-adobe-down-over-8-on-guidance-shortfall?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/closing-bell-movers-adobe-down-over-8-on-guidance-shortfall?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2458330243.SGD","LU0868494708.USD","LU0170899867.USD","LU2458330169.SGD","LU0889565833.HKD","LU0792757196.USD","LU1674673428.USD","LU0472753341.HKD","SGXZ99366536.SGD","IE0009356076.USD","LU0348723411.USD","LU0861579265.USD","LU1815333072.USD","LU1674673691.USD","LU1267930730.SGD","LU1267930813.SGD","LU0158827948.USD","TELO","LU1720051017.SGD","LU1548497426.USD","LU1778281490.HKD","LU0234572021.USD","LU2317271919.USD","LU1712237335.SGD","LU0198837287.USD","ADBE","BK4588","LU0106261372.USD","BK4528","IE00B19Z9505.USD","BK4567","LU1623119135.USD","LU0234570918.USD","LU2125154935.USD","LU0157215616.USD","BK4581","SG9999001424.SGD","LU0320765059.SGD","LU1691799644.USD","LU0082616367.USD","LU0557290698.USD","LU1720051108.HKD","LU0942090050.USD","BK4566","SGXZ51526630.SGD","LU0965509283.SGD","LU0965509101.SGD","BK4592","BK4585","LU0069063385.USD"],"gpt_icon":0},{"id":"2490811433","title":"Telomir Pharmaceuticals enters into stock purchase agreement for $1M","url":"https://stock-news.laohu8.com/highlight/detail?id=2490811433","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490811433?lang=en_us&edition=fundamental","pubTime":"2024-12-12 06:55","pubTimestamp":1733957710,"startTime":"0","endTime":"0","summary":"In a regulatory filing, the company states: “On December 9, 2024, Telomir Pharmaceuticals (TELO) entered into a Stock Purchase Agreement with a cer...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/telomir-pharmaceuticals-enters-into-stock-purchase-agreement-for-1m?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/telomir-pharmaceuticals-enters-into-stock-purchase-agreement-for-1m?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2488192340","title":"Telomir Pharmaceuticals' Shares Rally After Positive Results for Diabetes Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2488192340","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488192340?lang=en_us&edition=fundamental","pubTime":"2024-12-04 01:04","pubTimestamp":1733245440,"startTime":"0","endTime":"0","summary":"Shares of Telomir Pharmaceuticals climbed up 20% to $5.10 after the company said it saw positive pre-clinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several key parameters of Type 2 diabetes mellitus.The pre-clinical stage pharmaceutical company said the study demonstrated significant reductions in fasting plasma glucose levels to basal levels, improvements in oral glucose homeostasis, and the reversal of insulin resistance to near pre-diabetic levels.The Miami company said that these effects were also accompanied by increased survival rates in treated subjects, highlighting Telomir-1's ability to potentially address the underlying mechanisms of Type 2 diabetes.Telomir had its initial public offering in February, with 1 million shares pricing at $7 a share.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Telomir Pharmaceuticals' Shares Rally After Positive Results for Diabetes Treatment","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":50,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TELO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-04","symbol":"TELO","fiscalQuarterEnding":"2024/12","expectedEps":-0.05,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1738645200000,"reportTimeType":"post","actualEps":-0.1},{"market":"US","date":"2024-11-12","symbol":"TELO","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-0.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TELO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TELO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TELO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TELO","date":"2025-04-23","current":-4.680595,"percent":0.982206,"low":-83.265127,"twenty":-13.649831,"median":-7.833529,"eighty":-6.182048,"high":-4.268373,"avg":-13.606393,"sd":15.291067,"marketCap":77382944},"quantilePoints":[{"date":"2024-02-16","current":-56.39638,"twenty":-61.770129,"median":-49.049457,"eighty":-41.982417,"marketCap":238655100},{"date":"2024-02-23","current":-62.343889,"twenty":-63.029602,"median":-60.594622,"eighty":-46.922348,"marketCap":263823442},{"date":"2024-03-01","current":-63.46342,"twenty":-63.421438,"median":-62.588787,"eighty":-53.457611,"marketCap":268561012},{"date":"2024-03-08","current":-60.874505,"twenty":-63.351467,"median":-62.553802,"eighty":-58.915325,"marketCap":257605381},{"date":"2024-03-15","current":-45.550923,"twenty":-63.197532,"median":-61.749139,"eighty":-48.657621,"marketCap":192759889},{"date":"2024-03-22","current":-47.510102,"twenty":-63.029602,"median":-60.594622,"eighty":-45.928765,"marketCap":201050637},{"date":"2024-03-28","current":-35.580099,"twenty":-62.973626,"median":-56.39638,"eighty":-42.472212,"marketCap":150565904},{"date":"2024-04-05","current":-16.558518,"twenty":-62.833684,"median":-48.559663,"eighty":-36.881554,"marketCap":216450701},{"date":"2024-04-12","current":-18.574281,"twenty":-62.595784,"median":-46.390571,"eighty":-17.881143,"marketCap":242800474},{"date":"2024-04-19","current":-18.007992,"twenty":-62.469837,"median":-45.480952,"eighty":-18.234508,"marketCap":235398021},{"date":"2024-04-26","current":-15.402836,"twenty":-62.287913,"median":-41.632564,"eighty":-16.272973,"marketCap":201343774},{"date":"2024-05-03","current":-15.493668,"twenty":-61.8401,"median":-38.868721,"eighty":-15.530047,"marketCap":202531127},{"date":"2024-05-10","current":-14.814122,"twenty":-61.126399,"median":-34.985348,"eighty":-15.280653,"marketCap":193648183},{"date":"2024-05-17","current":-9.713938,"twenty":-60.762552,"median":-20.205194,"eighty":-14.460757,"marketCap":183044909},{"date":"2024-05-24","current":-9.899514,"twenty":-60.034856,"median":-18.959358,"eighty":-13.282876,"marketCap":186541828},{"date":"2024-05-31","current":-9.333828,"twenty":-58.635442,"median":-18.087272,"eighty":-12.474215,"marketCap":175882295},{"date":"2024-06-07","current":-8.139601,"twenty":-55.220872,"median":-16.988785,"eighty":-10.490343,"marketCap":153378836},{"date":"2024-06-14","current":-8.846709,"twenty":-50.518842,"median":-16.275148,"eighty":-9.899514,"marketCap":166703252},{"date":"2024-06-21","current":-7.888185,"twenty":-49.343334,"median":-15.720184,"eighty":-9.713341,"marketCap":148641266},{"date":"2024-06-28","current":-6.725384,"twenty":-48.853539,"median":-15.601263,"eighty":-9.547532,"marketCap":126730003},{"date":"2024-07-05","current":-5.892568,"twenty":-48.069868,"median":-15.505107,"eighty":-8.956704,"marketCap":111036802},{"date":"2024-07-12","current":-6.30112,"twenty":-47.510102,"median":-15.402836,"eighty":-8.799568,"marketCap":118735354},{"date":"2024-07-15","current":-6.489682,"twenty":-47.286196,"median":-15.301017,"eighty":-8.774426,"marketCap":122288531},{"date":"2024-08-02","current":-5.444733,"twenty":-47.06229,"median":-15.199198,"eighty":-8.702145,"marketCap":102598005},{"date":"2024-08-09","current":-6.693957,"twenty":-46.306606,"median":-14.519651,"eighty":-8.457014,"marketCap":126137807},{"date":"2024-08-16","current":-6.398398,"twenty":-45.928765,"median":-13.704195,"eighty":-7.938657,"marketCap":119919746},{"date":"2024-08-23","current":-8.941959,"twenty":-45.494946,"median":-12.939705,"eighty":-7.938657,"marketCap":167591547},{"date":"2024-08-30","current":-8.278421,"twenty":-44.739262,"median":-12.447033,"eighty":-7.964258,"marketCap":155155425},{"date":"2024-09-06","current":-8.088839,"twenty":-43.31186,"median":-11.665555,"eighty":-7.896719,"marketCap":151602247},{"date":"2024-09-13","current":-9.384317,"twenty":-41.324693,"median":-10.284417,"eighty":-7.947556,"marketCap":175882295},{"date":"2024-09-20","current":-10.585004,"twenty":-39.855308,"median":-9.907371,"eighty":-8.02294,"marketCap":198385753},{"date":"2024-09-27","current":-10.20584,"twenty":-38.889712,"median":-10.154737,"eighty":-8.063561,"marketCap":191279398},{"date":"2024-10-04","current":-8.81557,"twenty":-38.183009,"median":-10.103633,"eighty":-8.098318,"marketCap":165222762},{"date":"2024-10-11","current":-7.899257,"twenty":-35.461149,"median":-9.878893,"eighty":-8.063561,"marketCap":148049070},{"date":"2024-10-18","current":-7.614883,"twenty":-34.747448,"median":-9.758093,"eighty":-7.905576,"marketCap":142719303},{"date":"2024-10-25","current":-6.651174,"twenty":-31.113958,"median":-9.674022,"eighty":-7.796016,"marketCap":124657316},{"date":"2024-10-31","current":-6.967144,"twenty":-20.386406,"median":-9.548188,"eighty":-7.662279,"marketCap":130579279},{"date":"2024-11-08","current":-6.619577,"twenty":-20.023981,"median":-9.479108,"eighty":-7.520092,"marketCap":124065120},{"date":"2024-11-15","current":-5.106573,"twenty":-19.208525,"median":-9.44751,"eighty":-7.093532,"marketCap":117254863},{"date":"2024-11-22","current":-5.764237,"twenty":-18.959358,"median":-9.384317,"eighty":-6.945374,"marketCap":132355868},{"date":"2024-11-29","current":-5.132363,"twenty":-18.651296,"median":-9.321123,"eighty":-6.820757,"marketCap":117847059},{"date":"2024-12-06","current":-7.18273,"twenty":-18.184674,"median":-8.949331,"eighty":-6.737955,"marketCap":164926663},{"date":"2024-12-13","current":-6.563751,"twenty":-18.023848,"median":-8.846709,"eighty":-6.723181,"marketCap":150713953},{"date":"2024-12-20","current":-5.854505,"twenty":-17.536839,"median":-8.807569,"eighty":-6.690814,"marketCap":134428555},{"date":"2024-12-27","current":-6.20268,"twenty":-16.902731,"median":-8.783855,"eighty":-6.673736,"marketCap":142423205},{"date":"2025-01-03","current":-5.248422,"twenty":-16.522185,"median":-8.658147,"eighty":-6.652312,"marketCap":120511942},{"date":"2025-01-10","current":-5.545016,"twenty":-16.390671,"median":-8.634211,"eighty":-6.56633,"marketCap":127322200},{"date":"2025-01-17","current":-6.17689,"twenty":-16.023715,"median":-8.578593,"eighty":-6.40052,"marketCap":141831009},{"date":"2025-01-24","current":-6.154861,"twenty":-15.788139,"median":-8.438158,"eighty":-6.37032,"marketCap":141325187},{"date":"2025-01-31","current":-5.856836,"twenty":-15.652229,"median":-8.317918,"eighty":-6.30112,"marketCap":134482072},{"date":"2025-02-07","current":-8.137034,"twenty":-15.550297,"median":-8.296736,"eighty":-6.297394,"marketCap":134527272},{"date":"2025-02-14","current":-7.686977,"twenty":-15.516547,"median":-8.278421,"eighty":-6.30112,"marketCap":127086605},{"date":"2025-02-21","current":-7.524956,"twenty":-15.498244,"median":-8.185313,"eighty":-6.30311,"marketCap":124407964},{"date":"2025-02-28","current":-7.038894,"twenty":-15.466486,"median":-8.136234,"eighty":-6.326029,"marketCap":116372043},{"date":"2025-03-07","current":-7.452947,"twenty":-15.414207,"median":-8.073041,"eighty":-6.362583,"marketCap":123217457},{"date":"2025-03-14","current":-9.055151,"twenty":-15.239926,"median":-8.088839,"eighty":-6.384542,"marketCap":149706235},{"date":"2025-03-21","current":-7.344933,"twenty":-15.036107,"median":-8.052132,"eighty":-6.396338,"marketCap":121431697},{"date":"2025-03-28","current":-7.23692,"twenty":-14.850364,"median":-8.047023,"eighty":-6.406885,"marketCap":119645937},{"date":"2025-04-04","current":-5.11265,"twenty":-14.342969,"median":-7.97035,"eighty":-6.362583,"marketCap":84525985},{"date":"2025-04-11","current":-4.770606,"twenty":-14.080211,"median":-7.888185,"eighty":-6.296505,"marketCap":78871078},{"date":"2025-04-17","current":-4.48257,"twenty":-13.840104,"median":-7.867,"eighty":-6.248934,"marketCap":74109050},{"date":"2025-04-23","current":-4.680595,"twenty":-13.649831,"median":-7.833529,"eighty":-6.182048,"marketCap":77382944}],"updateTime":1745493449735}}}